The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study
| Autor: | Deni Aldo Procaccini, Giuseppe Gatta, Maria Ktena, Loreto Gesualdo, Mimmo Vigilante, Giovanna Salatino, Elvira Grandone, Maurizio Margaglione, Filippo Aucella, Carmine Stallone, Alva De Min, Mauro Forcella |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.medical_treatment Population Polymorphism Single Nucleotide Renal Dialysis Cause of Death Internal medicine medicine Humans Risk factor education Methylenetetrahydrofolate Reductase (NADPH2) Dialysis Cause of death Transplantation education.field_of_study biology business.industry Mortality rate Middle Aged medicine.disease Survival Analysis Endocrinology Cardiovascular Diseases Nephrology Methylenetetrahydrofolate reductase biology.protein Female Gene polymorphism business Peritoneal Dialysis Follow-Up Studies Kidney disease |
| Zdroj: | Nephrology Dialysis Transplantation. 20:382-386 |
| ISSN: | 1460-2385 0931-0509 |
| Popis: | BACKGROUND Although the methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism has been identified as an independent cardiovascular risk factor (CRF) in the general population and among uraemic subjects, the validity of this association remains controversial. METHODS To verify this hypothesis, we enrolled all subjects on maintenance dialysis treatment from a specific Italian district. We also enrolled, from the same area, 1307 subject to serve as controls. Genomic DNA was obtained and MTHFR C677T gene polymorphisms were determined. After a baseline evaluation, patients were followed-up for 37+/-13 months, and all cardiovascular events and causes of mortality were recorded. RESULTS A total of 461 patients (417 on haemodialysis and 44 on peritoneal dialysis) were investigated, and these included patients with and without cardiovascular diseases at baseline. At enrollment, mean age was 58.8+/-15.6 years and dialytic age was 82+/-69 months. Genotype frequencies were not different between controls and uraemics. During the follow-up, the mean mortality rate was 8.81%/year, with cardiovascular events as the most frequent cause of death (n = 68, 56.6%). There was no relationship between the MTHFR genotype and cardiovascular morbidity, overall mortality or cardiovascular mortality. CONCLUSIONS In end-stage renal disease, MTHFR C677T polymorphisms were not associated with cardiovascular disease or mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|